ANG-3777, is potentially a first-in-class hepatocyte growth factor (HGF) mimetic. We engineered ANG-3777 to mimic the biological activity of HGF in activating critical pathways in the body’s natural organ repair process following an acute organ injury. ANG-3777 is an investigational product and is not approved by any regulatory authority. In November 2020, Angion and Vifor signed a license agreement related to ANG-3777.
ANG-3070, is a highly selective, orally-bioavailable small molecule tyrosine kinase receptor inhibitor developed internally as a potential treatment for fibrotic diseases, particularly in the lung and kidney. ANG-3070 is an investigational product and is not approved by any regulatory authority.
The initial focus for our ROCK2 program is expected to be on fibrotic indications such as chronic kidney disease, IPF and nonalcoholic steatohepatitis (NASH). Given the heterogeneity of these diseases, we believe development of this program will benefit from our precision medicine approach and use of established clinical biomarkers.
We are leveraging our extensive experience in developing cytochrome P450 modulators to develop compounds with improved specificity for CYP11B2 relative to CYP11B1. In non-human primate models, one of our lead test compounds markedly reduced aldosterone production following an ACTH challenge while having a minimal impact on cortisol production.